By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Media HydeMedia Hyde
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Font ResizerAa
Media HydeMedia Hyde
Font ResizerAa
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Follow US
© 2026 Media Hyde Network. All Rights Reserved.
HeadlineHealth

Moderna shares surge after melanoma vaccine succeeds in large trial

Last updated: August 19, 2026 10:13 pm
Haris Ali
Share
Moderna shares surge after melanoma vaccine succeeds in large trial
Moderna shares surge after melanoma vaccine succeeds in large trial
SHARE

Moderna shares climbed 8% in pre-market trading Tuesday after the company reported long-term success for its experimental mRNA melanoma vaccine. The data, presented at a major oncology conference, confirms the treatment—when paired with Merck’s Keytruda—significantly lowers the risk of death or recurrence in high-risk patients.

Three years after the initial treatment, patients receiving the combination therapy showed a 49% reduction in the risk of recurrence or death compared to those treated with Keytruda alone. For those whose cancer had already spread to lymph nodes, the results were even more pronounced.

The findings offer a critical lifeline for patients battling stage III or IV melanoma. Standard immunotherapy often fails to prevent the disease from returning, leaving patients with few options once the cancer begins to spread. Moderna’s approach, which essentially trains the immune system to hunt down specific cancer cells using the patient’s own genetic profile, is moving closer to a regulatory green light.

“We are seeing a durable benefit that holds up over time,” said a senior oncology researcher involved in the study. “This isn’t just about shrinking tumors; it’s about keeping the cancer from ever coming back.”

The partnership between Moderna and Merck has been a high-stakes gamble. By integrating mRNA technology—the same platform used for Moderna’s COVID-19 vaccine—into personalized cancer care, the companies are betting on a shift in how oncology treats solid tumors. If the FDA grants accelerated approval based on these late-stage results, it would mark the first time a personalized mRNA cancer vaccine hits the commercial market.

Despite the optimism, manufacturing remains the primary hurdle. Each dose must be custom-made for the individual patient, requiring a complex, weeks-long process of sequencing a patient’s tumor and synthesizing the corresponding mRNA. Scaling this process to meet global demand without compromising quality is a challenge that has plagued personalized medicine for decades.

For investors, the stock surge signals renewed confidence in Moderna’s pipeline beyond respiratory viruses. The company has spent years trying to prove its mRNA platform works for diseases other than COVID-19. With this trial, they finally have the data to back the claim.

The companies expect to initiate additional trials for other types of cancer later this year. For now, the focus remains on finalizing the data package for regulators, potentially changing the standard of care for thousands of melanoma patients by 2025.

Share This Article
Email Copy Link Print
Previous Article Karachi Schools Ordered to Keep CNG and LPG Out of Student Transport Karachi Schools Ordered to Keep CNG and LPG Out of Student Transport
Next Article Police arrest four in Quetta over Asma Aman kidnapping Police arrest four in Quetta over Asma Aman kidnapping
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sponsored Ads

Stay Connected

FacebookLike
XFollow
InstagramFollow
YoutubeSubscribe
WhatsAppFollow
ThreadsFollow
Panchayat Season 5 Release Date Announced Jitendra Kumar and Neena Gupta Return to Phulera
Panchayat Season 5 Release Date Announced Jitendra Kumar and Neena Gupta Return to Phulera
Entertainment
November 18, 2026
Nameer Khan Reveals His Journey from Software Engineer to Actor
Nameer Khan Reveals His Journey from Software Engineer to Actor
Entertainment
November 18, 2026
Aiman Khan and Muneeb Butt Honoured at British Parliament
Aiman Khan and Muneeb Butt Honoured at British Parliament
Entertainment
November 18, 2026
PTI Questions Bilawal Bhutto-Zardari Over Late Realisation of Public Hardships
PTI Questions Bilawal Bhutto-Zardari Over Late Realisation of Public Hardships
Politics
November 18, 2026
Nawaz Sharif Vows to Accelerate Development in Azad Kashmir Under 100-Day Plan
Nawaz Sharif Vows to Accelerate Development in Azad Kashmir Under 100-Day Plan
Politics
November 18, 2026
Pakistan faces internet slowdown after submarine cable develops fault
Pakistan faces internet slowdown after submarine cable develops fault
Headline Technology
November 18, 2026

You Might Also Like

Fuel Pricing Breakdown: Taxes and Margins Outweigh Cost of Refined Petrol
EconomyHeadline

Fuel Pricing Breakdown: Taxes and Margins Outweigh Cost of Refined Petrol

By
Haris Ali
Land Water Storage is Driving Sea Level Rise, New Study Finds
Climate and WeatherHeadline

Land Water Storage is Driving Sea Level Rise, New Study Finds

By
Haris Ali
Health

Karachi: 200 Children Infected with HIV Due to Use of Contaminated Syringes

By
Neha Ashraf
How to register complaint in Pakistan’s first virtual women police station
Court & CrimeHeadline

How to register complaint in Pakistan’s first virtual women police station

By
Ayesha Masood
Media Hyde Media Hyde Dark
Facebook Twitter Youtube Rss Medium

About US

Media Hyde Network: Your instant connection to breaking stories and live updates. Stay informed with our real-time coverage across politics, tech, entertainment, and more. Your reliable source for 24/7 News.

Top Categories
  • Headline
  • Politics
  • Entertainment
  • Education
  • Sports
  • Religious
  • Metropolitan
  • Climate and Weather
Usefull Links
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Cookies Policy
  • Advertising Policy
  • Terms & Conditions

© 2025 Media Hyde Network. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?